Final Results for 12 months to 31 December 2020 and Notice of AGM
RNS & Investor News
Head of Quality & Operations appointment
08 October 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces the appointment of Aneta Zlotkowska as Head of Quality & Operations.
Aneta joins OptiBiotix from a position as Lead Development Manager at Tesco Plc, one of the world's largest retailers of consumer goods where her main responsibilities were within the distribution business unit in logistics and operations. Prior to working for Tesco, Aneta was a Quality Assurance and Purchasing Manager at Cornelius Group Plc where she has also held the positions of Senior Supply Chain Executive and Supply Chain Manager. Aneta holds a CIPS Diploma in Procurement and Supply Chain Management and has completed HACCP and BRC Third Party Auditor courses by the BRC Academy.
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "Given OptiBiotix's rapid international expansion with the announcements of various distribution and manufacturing agreements for SlimBiome®, OptiBiome® and WellBiome® as well as commercial launches of finished products containing OptiBiotix's technology in the UK (RNS: 7 January 2020) and the USA & Canada (RNS: 4 May 2020), we feel the need to appoint a full-time employee with the relevant skillset to manage and lead OptiBiotix's quality management system and operations.
"Aneta will join the Company on 1 January 2021 and will work towards ensuring timely deliveries of high-quality ingredients to OptiBiotix's partners around the world. Moreover, Aneta is tasked with attaining a BRC certification for OptiBiotix Ltd."
OptiBiotix Health plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Walbrook PR Ltd
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than sixty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The current areas of focus for the business include obesity, cardiovascular health, diabetes, digestive health, and health and wellbeing. .
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020